New York Court Dismisses Cancer Case Against 3M and Others

A New York appellate court has dismissed a significant cancer-related lawsuit against 3M Company and several other defendants. The court's ruling, issued on May 26, 2026, found that the plaintiffs did not provide sufficient evidence to support their claims that exposure to certain solvents caused cancer. This decision affects not only the plaintiffs but also sets a precedent for similar cases involving chemical exposure and health risks.

The case, known as Lotrean v. 3M Co., involved Marinel Lotrean and others who claimed they developed Myelodysplastic Syndrome (MDS) due to exposure to solvents used in an autobody shop owned by Lotrean's father. The plaintiffs argued that the solvents contained benzene, a known carcinogen, and that their exposure led to their medical condition. The court's decision is significant because it addresses the complexities of proving causation in toxic tort cases.

Background

The plaintiffs in this case, Marinel Lotrean and his family, filed a lawsuit against 3M Company, E.I. du Pont de Nemours and Company, Rust-Oleum Corporation, and Zep, Inc. They alleged that exposure to products containing benzene resulted in MDS, a type of cancer that affects blood and bone marrow. The plaintiffs claimed that they were exposed to these harmful substances while working in an autobody shop, where various solvents were used for cleaning and painting vehicles.

The lawsuit was initiated in the New York Supreme Court, where the plaintiffs sought damages for their health conditions. The defendants responded with motions for summary judgment, arguing that the plaintiffs failed to establish a direct link between their products and the alleged health risks. The lower court initially denied these motions, leading the defendants to appeal the decision to the Appellate Division of the Supreme Court of the State of New York.

The case reached the appellate court after the plaintiffs presented expert testimony that aimed to connect their exposure to solvents with the development of MDS. However, the court scrutinized the evidence presented and found that the plaintiffs' arguments did not sufficiently demonstrate that the specific solvents used were carcinogenic.

The Ruling

The appellate court unanimously reversed the lower court's decision, granting the defendants' motions for summary judgment and dismissing the complaint. The court ruled that the defendants had made a prima facie showing of entitlement to summary judgment by providing expert affidavits and studies that demonstrated the solvents in their products were not carcinogenic. The court stated, "Defendants made a prima facie showing of entitlement to summary judgment by submitting expert affidavits and studies demonstrating that the component solvents in their products...are not carcinogenic."

The judges noted that the plaintiffs failed to raise a genuine issue of fact regarding the relationship between their exposure to solvents and the risk of developing MDS. The court pointed out that the plaintiffs' experts focused on the general relationship between benzene and MDS, rather than establishing that the specific solvents contained harmful levels of benzene. The court emphasized that the plaintiffs' reliance on studies that did not directly relate to their case was insufficient to support their claims.

As a result, the appellate court concluded that the plaintiffs did not create a triable issue of fact on the question of general causation. The ruling highlighted the importance of providing concrete evidence when alleging health risks associated with chemical exposure.

Impact

This ruling has significant implications for future toxic tort cases, particularly those involving claims of cancer due to chemical exposure. The decision underscores the necessity for plaintiffs to present robust scientific evidence linking specific chemicals to health conditions. It sets a precedent that may make it more challenging for individuals to win similar cases without clear, direct evidence of causation.

Moreover, the court's decision may discourage potential plaintiffs from pursuing similar lawsuits unless they can provide strong scientific backing for their claims. This ruling could also impact companies in the chemical and manufacturing sectors, as they may face fewer lawsuits if plaintiffs struggle to meet the evidentiary standards established by this case.

What's Next

The plaintiffs in Lotrean v. 3M Co. have the option to appeal this ruling to a higher court, although details were not available in the court filing regarding any plans for further legal action. Additionally, there may be related cases pending that could further explore the issues of chemical exposure and health risks.